Company / Capital Expenditures
Axsome Therapeutics, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$480.0K
FY2025
5-year range
$270.0K / $702.0K
FY2021-FY2025
Trend
+77.8%
vs FY2024
Sector context
#139 of 194
Health Care
What the data says
At $480,000, Axsome Therapeutics, Inc.'s capital expenditures ranks #139 of 194 in the Health Care sector. Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $480,000.
Based on SEC 10-K filings.
$480,000 in FY2025 with a 5-year CAGR of +59.9%.
Declined from $582,000 to $480,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -11.9%
- 5-Year CAGR
- +59.9%
- 10-Year CAGR
- -
Sector benchmark
#139 of 194 in Health CareTop 72% of 194This company $480.0K Sector average $117.5M
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +59.9%, indicating consistent growth.
- In FY2025, capital expenditures increased 77.8% year-over-year.
- Ranks #139 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $480.0K | +77.8% |
| FY2024 | $270.0K | -53.6% |
| FY2023 | $582.0K | -17.1% |
| FY2022 | $702.0K | +127.9% |
| FY2021 | $308.0K | +571.2% |
| FY2020 | $45.9K | +184.7% |
| FY2019 | $16.1K | -50.7% |
| FY2018 | $32.7K | +230.3% |
| FY2017 | $9.9K | -90.5% |
| FY2016 | $104.6K | +417.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026